NasdaqGS:ILMNLife Sciences
Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And SomaLogic Integration
Why Illumina stock is back in focus
Illumina (ILMN) is back on investor watchlists after first quarter 2026 results topped market expectations, the company raised full year guidance, and management highlighted firm demand in clinical sequencing.
See our latest analysis for Illumina.
The share price has moved to $139.07, with a 7 day share price return of 9.57% and a 30 day gain of 9.18%, suggesting short term momentum. This compares with a 1 year total shareholder return of 86.60% and weaker...